GLP-2 (Teduglutide-like)
NeuroprotectionResearchers tracking GLP-2 (Teduglutide-like) for cognitive and neurological endpoints describe a restorative rather than stimulant phenotype. The compound supports recovery from neurological injury, modulates neuroinflammatory tone, and stabilises monoamine and HPA-axis signalling. Dosing at Research dose 0.05 mg/kg/day (teduglutide approved) 1x daily subq via subq delivers exposure consistent with the ~7 min native; analogues 1.3-2 hr half-life and the typical 8-12 week cycle pattern used in nootropic-research protocols.
Key Takeaways
Cognitive lens: GLP-2 (Teduglutide-like) acts as a modulator with both restorative and modest activating components for cognitive endpoints. CNS access pattern: BBB transport plus vagal-afferent gut-brain signalling and cerebral vascular effects. Mechanism: GLP-2 receptor agonist expressed on subepithelial myofibroblasts and enteric neurons. Neuro dose: Research dose 0.05 mg/kg/day (teduglutide approved) 1x daily subq via subq; cognitive effects accumulate across 4-8 weeks. Cognitive stack partners: Semax, Selank, Semax + Selank Blend.
GLP-2 (Teduglutide-like)'s neurological relevance starts with how the compound reaches the central nervous system. GLP-2 receptor agonist expressed on subepithelial myofibroblasts and enteric neurons. Stimulates crypt cell proliferation, villus height, and intestinal blood flow. Reduces gut permeability and supports epithelial repair. Direct blood-brain barrier transport is rarely the dominant route for peptide compounds; vagal-afferent gut-brain signalling and effects on cerebral vasculature where the barrier is locally compromised typically produce the CNS phenotype. The detail follows.
Cerebral perfusion and the structural cognitive substrate
Cognitive function depends on adequate cerebral perfusion, intact endothelial signalling, and a low chronic-inflammatory tone in the brain parenchyma. GLP-2 (Teduglutide-like), with its GLP-2 receptor agonist expressed on subepithelial myofibroblasts and enteric neurons Stimulates crypt cell proliferation, villus height, and intestinal blood flow. Reduces gut permeability and supports epithelial repair. mechanism, contributes to this substrate rather than producing acute stimulant-like activation. Across the cognitive applications outlined below, what users describe is restoration of baseline rather than amplification above it. The ~7 min native; analogues 1.3-2 hr pharmacokinetic profile supports this restorative rather than stimulant phenotype.
Inflammation and neurological recovery
One of the most replicated effects across compounds in GLP-2 (Teduglutide-like)'s class (Intestinotrophic peptide) is reduction of inflammatory cytokines (TNF-α, IL-1β, IL-6) in tissues including the central nervous system. For users whose cognitive complaints track with chronic low-grade neuroinflammation — long-COVID, post-viral cognitive fog, post-concussion lingering symptoms, chronic stress — this anti-inflammatory layer is often the most operationally relevant mechanism. GLP-2 (Teduglutide-like)'s contribution operates on the same axis at Research dose 0.05 mg/kg/day (teduglutide approved) per dose.
Central nervous system access
GLP-2 (Teduglutide-like) reaches the central nervous system through one or more of three documented routes: direct blood-brain barrier transport, vagal-afferent signalling via the gut-brain axis, and direct action on cerebral vasculature in regions where the barrier is locally compromised. The compound's subq route(s) and ~7 min native; analogues 1.3-2 hr half-life set the timeline for CNS exposure. GLP-2 receptor agonist expressed on subepithelial myofibroblasts and enteric neurons. The CNS-relevant phenotype that emerges from this mechanism is the substrate of the cognitive effects described below.
For cognitive recovery, GLP-2 (Teduglutide-like) is most-relevant in users whose cognitive complaints track with chronic neuroinflammation or post-injury recovery. Effect size is modest but consistent across well-tolerated dose ranges, with typical response window of 4–8 weeks.
Where GLP-2 (Teduglutide-like) is used for post-tbi recovery, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.
BDNF Support is one of the more-reported subjective benefits of GLP-2 (Teduglutide-like) across cognitive-focused user cohorts. The mechanism is plausible given the compound's neurotrophic and anti-inflammatory profile; the effect size depends substantially on baseline status.
For mood stabilisation, GLP-2 (Teduglutide-like) is most-relevant in users whose cognitive complaints track with chronic neuroinflammation or post-injury recovery. Effect size is modest but consistent across well-tolerated dose ranges, with typical response window of 4–8 weeks.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | Research dose 0.05 mg/kg/day (teduglutide approved) | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | Research dose 1.05 mg/kg/day (teduglutide approved) | 4–6 weeks initial cycle |
| Neuroprotection focus | SubQ | Research dose 0.05 mg/kg/day (teduglutide approved) | 1x daily SubQ |
| Maintenance phase | SubQ | Research dose 1.05 mg/kg/day (teduglutide approved) | Ongoing with periodic pauses |
Dose timing for GLP-2 (Teduglutide-like) is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
GLP-2 (Teduglutide-like) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the cognitive neuroscience community.
- GLP-2 (Teduglutide-like) + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with GLP-2 (Teduglutide-like)'s mechanism in cognitive / neurological protocols.
- GLP-2 (Teduglutide-like) + Selank: Modulates GABA-A receptor systems indirectly. Pairs naturally with GLP-2 (Teduglutide-like)'s mechanism in cognitive / neurological protocols.
- GLP-2 (Teduglutide-like) + Semax + Selank Blend: Semax raises BDNF and modulates dopamine systems; Selank stabilises GABAergic and serotonergic tone. Pairs naturally with GLP-2 (Teduglutide-like)'s mechanism in cognitive / neurological protocols.
- GLP-2 (Teduglutide-like) + DSIP: Mechanism remains incompletely characterised. Pairs naturally with GLP-2 (Teduglutide-like)'s mechanism in cognitive / neurological protocols.
Colorectal polyp surveillance required (long-term mitogenic effects on gut epithelium). Risk of intestinal obstruction. Pancreatitis risk.
Lens-specific safety considerations for cognitive / neurological use of GLP-2 (Teduglutide-like): Colorectal polyp surveillance required (long-term mitogenic effects on gut epithelium). Risk of intestinal obstruction. Pancreatitis risk. Additional cognitive / neurological monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| GLP-2 (Teduglutide-like) | Intestinotrophic peptide | ~7 min native; analogues 1.3-2 hr | Neuroprotection |
| Semax | ACTH-derived nootropic heptapeptide | CNS effect hours; plasma minutes | A Russian-developed analogue of ACTH(4-10) extended with a Pro-Gly-Pro tail for proteolytic stability — a clinically used nootropic and stroke recovery agent |
| Selank | Tuftsin-derived heptapeptide anxiolytic | CNS effect lasts hours; plasma short | A Russian-developed heptapeptide derived from tuftsin — anxiolytic without sedation, supported by clinical trial data in generalised anxiety disorder |
| DSIP | Neuropeptide (sleep) | ~7 min plasma; CNS effects longer | A short neuropeptide isolated from sleeping rabbits in 1977, of interest for its modulation of delta-wave sleep and stress resilience |
| Pinealon | Khavinson tripeptide (pineal-derived) | Short plasma; durable tissue effects | A Khavinson pineal-derived tripeptide of glutamate-aspartate-arginine, studied for neuroprotection and cognitive function in aged and ischemic models |
Is GLP-2 (Teduglutide-like) a true nootropic?
Best route for cognitive applications — injection or oral?
Does GLP-2 (Teduglutide-like) cross the blood-brain barrier?
Can GLP-2 (Teduglutide-like) be stacked with other nootropics?
What does GLP-2 (Teduglutide-like) stack well with?
What is the regulatory status of GLP-2 (Teduglutide-like)?
Start a GLP-2 (Teduglutide-like) Protocol
Alukard provides physician-supervised cognitive protocols with GMP-certified GLP-2 (Teduglutide-like) and GMP-certified compounds and comprehensive neurological assessments.
Get ProtocolQuick Facts
- Molecular weight
- ~3766 Da
- Sequence length
- 33 aa
- Half-life
- ~7 min native; analogues 1.3-2 hr
- WADA
- Not on prohibited list
- FDA
- Approved (Teduglutide / Gattex for SBS)
- Research
- Phase III in SBS; off-label gut research
Stack Partners
All cognitive / neurological applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for GLP-2 (Teduglutide-like) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Cognitive / Neurological Protocol for GLP-2 (Teduglutide-like)
Alukard provides physician-supervised cognitive protocols with GMP-certified compounds and comprehensive neurological assessments.
HIPAA Compliant · GMP Certified · Physician Supervised